Skip to main content


Table 2 Treatments used adjunctively with DEX implant for complications of RVO in treatment-naïve patients

From: Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study

Treatments used in addition to DEX implant Treatment-naïve patients
(N = 39)
Any treatment, n (%) 27 (69.2)
Intravitreal injection  
 Anti-VEGF, n (%) 23 (59.0)
  Ranibizumab, n (%) 16 (41.0)
  Bevacizumab, n (%) 9 (23.1)
   Mean number of ranibizumab or bevacizumab injections in patients receiving anti-VEGF 3.2
   Range 1–6
Laser photocoagulation  
 Focal, n (%) 11 (28.2)
 Panretinal, n (%) 1 (2.6)
  1. DEX implant dexamethasone intravitreal implant, RVO retinal vein occlusion, VEGF vascular endothelial growth factor